APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma

Walker, Brian A., Wardell, Christopher P., Murison, Alex, Boyle, Eileen M., Begum, Dil B., Dahir, Nasrin M., Proszek, Paula Z., Melchor, Lorenzo +13 more·2015·Nature Communications

DOI 10.1038/ncomms7997

Cited by (313)

Items 101–200 of 313

APOBEC3: Friend or Foe in Human Papillomavirus Infection and Oncogenesis?
Cody J. Warren, Mario L. Santiago, Dohun Pyeon · 2022 · Annual Review of Virology
Reactivation of dormant anti-tumor immunity – a clinical perspective of therapeutic immune checkpoint modulation
Richard Greil, Evelyn Hutterer, Tanja Nicole Hartmann, Lisa Pleyer · 2017 · Cell Communication and Signaling
Conformational Switch Regulates the DNA Cytosine Deaminase Activity of Human APOBEC3B
Ke Shi, Özlem Demir, Michael A. Carpenter, Jeff Wagner, Kayo Kurahashi, Reuben S. Harris, Rommie E. Amaro, Hideki Aihara · 2017 · Scientific Reports
Mate pair sequencing outperforms fluorescence in situ hybridization in the genomic characterization of multiple myeloma
James B. Smadbeck, Jess F. Peterson, Kathryn E. Pearce, Beth A. Pitel, Andrea Lebron Figueroa, Michael Timm, Dragan Jevremović, Min Shi, A. Keith Stewart, Esteban Braggio et al. · 2019 · Blood Cancer Journal
The interesting relationship between APOBEC3 deoxycytidine deaminases and cancer: a long road ahead
Milaid Granadillo Rodríguez, Ben Flath, Linda Chelico · 2020 · Open Biology
Multiple myeloma risk variant at 7p15.3 creates an IRF4-binding site and interferes with CDCA7L expression
Ni Li, David C. Johnson, Niels Weinhold, James B. Studd, Giulia Orlando, Fabio Mirabella, Jonathan S. Mitchell, Tobias Meißner, Martin Kaiser, Hartmut Goldschmidt et al. · 2016 · Nature Communications
Prognostic factors for multiple myeloma in the era of novel therapies
Dimitrios C. Ziogas, Meletios Athanasios Dimopoulos, Efstathios Kastritis · 2018 · Expert Review of Hematology
Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer
Mairead Geraldine McNamara, Andre Lopes, Harpreet Singh Wasan, David Malka, David Goldstein, Jenny Shannon, Takuji Okusaka, Jennifer Jane Knox, Dorothea Wagner, Thierry André et al. · 2020 · Journal of Hepatology
Established and Novel Prognostic Biomarkers in Multiple Myeloma
Mark W. Bustoros, Tarek H. Mouhieddine, Alexandre Detappe, Irene M. Ghobrial · 2017 · American Society of Clinical Oncology Educational Book
Characterization of the mechanism by which the RB/E2F pathway controls expression of the cancer genomic DNA deaminase APOBEC3B
Pieter A. Roelofs, Chai Yeen Goh, Boon Haow Chua, Matthew C. Jarvis, Teneale A. Stewart, Jennifer L. McCann, Rebecca M. McDougle, Michael A. Carpenter, John W.M. Martens, Paul N. Span et al. · 2020 · eLife
The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma
Caleb K. Stein, Charlotte Pawlyn, Shweta S. Chavan, Leo Rasche, Niels Weinhold, Adam L. Corken, Amy F. Buros, Pieter Sonneveld, Graham Hunter Jackson, Ola Landgren et al. · 2017 · Oncotarget
Reconstructing the evolutionary history of multiple myeloma
Francesco Maura, Even Holth Rustad, Eileen Mary Boyle, Gareth John Morgan · 2020 · Best Practice & Research Clinical Haematology
Oncolytic Virotherapy as Promising Immunotherapy Against Cancer: Mechanisms of Resistance to Oncolytic Viruses
Nasser Hashemi Goradel, Arezoo Alizadeh, Shahnaz Hosseinzadeh, Mitra Taghipour, Zeinab Ghesmati, Arash Arashkia, Babak Negahdari · 2021 · Future Oncology
Genetic subtypes of smoldering multiple myeloma are associated with distinct pathogenic phenotypes and clinical outcomes
Bustoros, Mark, Anand, Shankara, Sklavenitis-Pistofidis, Romanos, Redd, Robert, Boyle, Eileen M., Zhitomirsky, Benny, Dunford, Andrew J., Tai, Yu-Tzu, Chavda, Selina J., Boehner, Cody et al. · 2022 · Nature Communications
Genomic landscape of multiple myeloma and its precursor conditions
Alberge, Jean-Baptiste, Dutta, Ankit K., Poletti, Andrea, Coorens, Tim H. H., Lightbody, Elizabeth D., Toenges, Rosa, Loinaz, Xavi, Wallin, Sofia, Dunford, Andrew, Priebe, Oliver et al. · 2025 · Nature Genetics
Current risk stratification and staging of multiple myeloma and related clonal plasma cell disorders
Saurabh Zanwar, S. Vincent Rajkumar · 2025 · Leukemia
Genomic Aberrations in Multiple Myeloma
Salomon Manier, Karma Ziad Salem, Siobhan V. Glavey, Aldo Maria Roccaro, Irene M. Ghobrial · 2016 · Cancer treatment and research
Endogenous APOBEC3B Overexpression Constitutively Generates DNA Substitutions and Deletions in Myeloma Cells
Hiroyuki Yamazaki, Kotaro Shirakawa, Tadahiko Matsumoto, Shigeki Hirabayashi, Yasuhiro Murakawa, Masayuki Kobayashi, Anamaria Daniela Sarca, Yasuhiro Kazuma, Hiroyuki Matsui, Wataru Maruyama et al. · 2019 · Scientific Reports
Aberrant BUB1 Overexpression Promotes Mitotic Segregation Errors and Chromosomal Instability in Multiple Myeloma
Yuto Fujibayashi, Reiko Isa, Daichi Nishiyama, Natsumi Sakamoto-Inada, Norichika Kawasumi, Junko Yamaguchi, Saeko Kuwahara‐Ota, Yayoi Matsumura‐Kimoto, Taku Tsukamoto, Yoshiaki Chinen et al. · 2020 · Cancers
Metabolic Effects of Recurrent Genetic Aberrations in Multiple Myeloma
Timon A. Bloedjes, Guus de Wilde, Jeroen E. J. Guikema · 2021 · Cancers
Utilizing next-generation sequencing in the management of multiple myeloma
Marta Lionetti, Antonino Neri · 2017 · Expert Review of Molecular Diagnostics
Germline APOBEC3B deletion increases somatic hypermutation in Asian breast cancer that is associated with Her2 subtype, PIK3CA mutations and immune activation
Jia Wern Pan, Muhammad Mamduh Ahmad Zabidi, Boon‐Keat Chong, Mei‐Yee Meng, Pei-Sze Ng, Siti Norhidayu Hasan, Bethan Sandey, Saira Bahnu, Pathmanathan Rajadurai, Cheng Har Yip et al. · 2021 · International Journal of Cancer
Activation induced cytidine deaminase: An old friend with new faces
Elif Çakan, Gürcan Günaydın · 2022 · Frontiers in Immunology
Genomic and immune determinants of resistance to daratumumab-based therapy in relapsed refractory multiple myeloma
Bachisio Ziccheddu, Claudia Giannotta, Mattia D’Agostino, Giuseppe Bertuglia, Elona Saraci, Stefania Oliva, Elisa Genuardi, Marios Papadimitriou, Benjamin T. Diamond, Paolo Corradini et al. · 2024 · Blood Cancer Journal
Neutral tumor evolution in myeloma is associated with poor prognosis
David C. Johnson, Oleg Lenive, Jonathan S. Mitchell, Graham Hunter Jackson, Roger G. Owen, Mark Trehane Drayson, Gordon Cook, John R Jones, Charlotte Pawlyn, Faith E. Davies et al. · 2017 · Blood
Treatment Strategies Considering Micro-Environment and Clonal Evolution in Multiple Myeloma
Kazuhito Suzuki, Kaichi Nishiwaki, Shingo Yano · 2021 · Cancers
APOBEC and Cancer Viroimmunotherapy: Thinking the Unthinkable
Richard G. Vile, Alan A. Melcher, Hardev Pandha, Kevin Joseph Harrington, José S. Pulido · 2021 · Clinical Cancer Research
Structure-Based Design of First-Generation Small Molecule Inhibitors Targeting the Catalytic Pockets of AID, APOBEC3A, and APOBEC3B
Justin J. King, Faezeh Borzooee, Junbum Im, Mahdi Asgharpour, Atefeh Ghorbani, Cody P. Diamond, Heather Fifield, Lesley Berghuis, Mani Larijani · 2021 · ACS Pharmacology & Translational Science
Emerging options in multiple myeloma: targeted, immune, and epigenetic therapies
Shaji Kunnathu Kumar · 2017 · Hematology
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy
Timothy J. Kottke, Jason M. Tonne, Laura Evgin, Christopher B. Driscoll, Jacob P. van Vloten, Victoria A. Jennings, Amanda L. Huff, Brady N. Zell, Jill Thompson, Phonphimon Wongthida et al. · 2021 · Nature Communications
m6A demethylation of cytidine deaminase APOBEC3B mRNA orchestrates arsenic-induced mutagenesis
Ming Gao, Zijuan Qi, Wenya Feng, Hongyang Huang, Zhijie Xu, Zheng Dong, Ming Xu, Jinxiang Han, Jake A. Kloeber, Jinzhou Huang et al. · 2022 · Journal of Biological Chemistry
Review of Multiple Myeloma Genetics including Effects on Prognosis, Response to Treatment, and Diagnostic Workup
Julia Erin Wiedmeier, Peter Leif Bergsagel · 2022 · Life
Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
Andrea Keppler‐Hafkemeyer, Christine Greil, Paul R. Wratil, Khalid Shoumariyeh, Marcel Stern, Annika Hafkemeyer, Driti Ashok, Alexandra Hollaus, Gaia Lupoli, Alina Priller et al. · 2022 · Nature Cancer
Protein kinase A inhibits tumor mutator APOBEC3B through phosphorylation
Tadahiko Matsumoto, Kotaro Shirakawa, Masaru Yokoyama, Hirofumi Fukuda, Anamaria Daniela Sarca, Sukenao Koyabu, Hiroyuki Yamazaki, Yasuhiro Kazuma, Hiroyuki Matsui, Wataru Maruyama et al. · 2019 · Scientific Reports
Designing Evolutionary-based Interception Strategies to Block the Transition from Precursor Phases to Multiple Myeloma
Francesco Maura, Ola Landgren, Gareth John Morgan · 2020 · Clinical Cancer Research
Young Myeloma Patients: A Systematic Review of Manifestations and Outcomes
Mégane Tanguay, Christophe Dagenais, Richard LeBlanc, Imran Ahmad, Jean‐Sébastien Claveau, Jean Roy · 2023 · Current Oncology
Understanding DNA Damage Response and DNA Repair in Multiple Myeloma
Cole Petrilla, Joshua Galloway, Ruchi Kudalkar, Aya Ismael, Francesca Cottini · 2023 · Cancers
Multiple Myeloma Genomics: A Systematic Review
Casey J. Weaver, Joseph D Tariman · 2017 · Seminars in Oncology Nursing
A Journey Through Myeloma Evolution: From the Normal Plasma Cell to Disease Complexity
Matteo Da Vià, Bachisio Ziccheddu, Akihiro Maeda, Filippo Bagnoli, Giulia Perrone, Niccolò Bolli · 2020 · HemaSphere
APOBEC3 Mediates Resistance to Oncolytic Viral Therapy
Amanda L. Huff, Phonphimon Wongthida, Timothy J. Kottke, Jill Thompson, Christopher B. Driscoll, Matthew R. Schuelke, Kevin G. Shim, Reuben S. Harris, Amy M. Molan, José S. Pulido et al. · 2018 · Molecular Therapy — Oncolytics
The DNA deaminase APOBEC3B interacts with the cell-cycle protein CDK4 and disrupts CDK4-mediated nuclear import of Cyclin D1
Jennifer L. McCann, Madeline M. Klein, Evelyn M. Leland, Emily K. Law, William L. Brown, Daniel J. Salamango, Reuben S. Harris · 2019 · Journal of Biological Chemistry
Drug Targeting of Genomic Instability in Multiple Myeloma
Meral Beksaç, Sevinç Ballı, Dilara Akcora Yildiz · 2020 · Frontiers in Genetics
Clonal Evolution of Multiple Myeloma—Clinical and Diagnostic Implications
Aleksander Salomon‐Perzyński, Krzysztof Jamroziak, Eliza Głodkowska‐Mrówka · 2021 · Diagnostics
Myeloma Genome Project Panel is a Comprehensive Targeted Genomics Panel for Molecular Profiling of Patients with Multiple Myeloma
Parvathi Sudha, Aarif Ahsan, Cody Ashby, Tasneem Kausar, Akhil Khera, Mohammad H. Kazeroun, Chih-Chao Hsu, Lin Wang, Evelyn Fitzsimons, Outi Salminen et al. · 2022 · Clinical Cancer Research
Germline Risk Contribution to Genomic Instability in Multiple Myeloma
Siegfried Janz, Fenghuang Zhan, Fumou Sun, Yan Cheng, Michael D. Pisano, Ye Yang, Hartmut Goldschmidt, Parameswaran Hari · 2019 · Frontiers in Genetics
Myc-Related Mitochondrial Activity as a Novel Target for Multiple Myeloma
Alejandra Ortiz-Ruiz, Yanira Ruiz‐Heredia, María Luz Morales, Pedro Aguilar-Garrido, Almudena García-Ortiz, Antonio Valeri, Carmen Bárcena, Rosa García-Martín, Vanesa Garrido, Laura Moreno et al. · 2021 · Cancers
Deciphering response dynamics and treatment resistance from circulating tumor DNA after CAR T-cells in multiple myeloma
Hitomi Hosoya, Mia A. Carleton, Kailee L. Tanaka, Brian J. Sworder, Shriya Syal, Bita Sahaf, Alisha M. Birk, Oscar Silva, Henning Stehr, Vanna N. Hovanky et al. · 2025 · Nature Communications
Guidelines for the testing and reporting of cytogenetic results for risk stratification of multiple myeloma: a report of the Cancer Genomics Consortium Plasma Cell Neoplasm Working Group
Xinyan Lu, Erica Andersen, Rahul Kumar Banerjee, Celeste Eno, Patrick R. Gonzales, Shaji Kunnathu Kumar, Angela M. Lager, Patricia Minehart Miron, Trevor J. Pugh, Fabiola Quintero‐Rivera et al. · 2025 · Blood Cancer Journal
Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism
Li Ni, David C. Johnson, Niels Weinhold, Scott T. Kimber, Sara E. Dobbins, Jonathan S. Mitchell, Ben Kinnersley, Amit Sud, Philip Law, Giulia Orlando et al. · 2017 · Cell Reports
MAGE-A inhibit apoptosis and promote proliferation in multiple myeloma through regulation of BIM and p21Cip1
Anna Huo-Chang Mei, Kaity Han-Yung Tung, Jessie Han, Deepak Perumal, Alessandro Laganà, Jonathan J. Keats, Daniel Auclair, Ajai Chari, Sundar Jagannath, Samir Sunil Parekh et al. · 2020 · Oncotarget
Structure-Guided Design of a Potent and Specific Inhibitor against the Genomic Mutator APOBEC3A
Juan Carlos Serrano, Dora von Trentini, Kiara N. Berríos, Aleksia Barka, Ivan J. Dmochowski, Rahul M. Kohli · 2022 · ACS Chemical Biology
Old and Young Actors Playing Novel Roles in the Drama of Multiple Myeloma Bone Marrow Microenvironment Dependent Drug Resistance
Sabrina Manni, Marilena Carrino, Gianpietro Semenzato, Francesco Piazza · 2018 · International Journal of Molecular Sciences
Directly targeting c-Myc contributes to the anti-multiple myeloma effect of anlotinib
Yang Cao, Huizhuang Shan, Meng Liu, Jia Liu, Zilu Zhang, Xiaoguang Xu, Yue Liu, Hanzhang Xu, Hu Lei, Miao Yu et al. · 2021 · Cell Death and Disease
Plasma cell myeloma: role of histopathology, immunophenotyping, and genetic testing
Megan J. Fitzpatrick, Valentina Nardi, Aliyah R. Sohani · 2021 · Skeletal Radiology
Suboptimal T-cell Therapy Drives a Tumor Cell Mutator Phenotype That Promotes Escape from First-Line Treatment
Laura Evgin, Amanda L. Huff, Timothy J. Kottke, Jill Thompson, Amy M. Molan, Christopher B. Driscoll, Matthew R. Schuelke, Kevin G. Shim, Phonphimon Wongthida, Elizabeth J. Ilett et al. · 2019 · Cancer Immunology Research
Molecular Pathogenesis of Multiple Myeloma
Maura, Francesco, Bergsagel, Peter Leif · 2024 · Hematology/Oncology Clinics of North America
The genetic landscape of 5T models for multiple myeloma
Ken Maes, Bram Boeckx, Philip Vlummens, Kim De Veirman, Eline Menu, Karin Vanderkerken, Diether Lambrechts, Elke De Bruyne · 2018 · Scientific Reports
Where We Stand With Precision Therapeutics in Myeloma: Prosperity, Promises, and Pipedreams
Darren Pan, Joshua Ryan Richter · 2022 · Frontiers in Oncology
Genomic Basis of Multiple Myeloma Subtypes from the MMRF CoMMpass Study
Sheri Skerget, Daniel Peñaherrera, Ajai Chari, Sundar Jagannath, David Samuel DiCapua Siegel, Ravi Vij, Gregory Joshua Orloff, Andrzej J. Jakubowiak, Rubén Niesvizky, Darla Liles et al. · 2021 · medRxiv
Aberrant APOBEC3C expression induces characteristic genomic instability in pancreatic ductal adenocarcinoma
Yunzhen Qian, Yitao Gong, Xuan Zou, Yu Liu, Yusheng Chen, Ruijie Wang, Zhengjie Dai, Yesiboli Tasiheng, Xuan Lin, Xu Wang et al. · 2022 · Oncogenesis
The FGF/FGFR/c-Myc axis as a promising therapeutic target in multiple myeloma
Arianna Giacomini, Sara Taranto, Giorgia Gazzaroli, Jessica Faletti, Davide Capoferri, Raffaella Marcheselli, Margherita Sciumé, Marco Presta, Antonio Sacco, Aldo Maria Roccaro · 2024 · Journal of Experimental & Clinical Cancer Research
Targeting transcription factors in multiple myeloma: evolving therapeutic strategies
Shirong Li, Sonia Vallet, Antonio Sacco, Aldo Maria Roccaro, Suzanne Lentzsch, Klaus Podar · 2019 · Expert Opinion on Investigational Drugs
Transcriptome-wide association study of multiple myeloma identifies candidate susceptibility genes
Molly Went, Ben Kinnersley, Amit Sud, David C. Johnson, Niels Weinhold, Asta Försti, Mark van Duin, Giulia Orlando, Jonathan S. Mitchell, Rowan Kuiper et al. · 2019 · Human Genomics
Proteome alterations associated with transformation of multiple myeloma to secondary plasma cell leukemia
Alexey Zatula, Aida Dikic, Celine Mulder, Animesh Sharma, Cathrine Broberg Vågbø, Mirta Mittelstedt Leal de Sousa, Anders Waage, Geir Slupphaug · 2016 · Oncotarget
Genomic Instability in Multiple Myeloma: A “Non-Coding RNA” Perspective
Elisa Taìana, Maria Eugenia Gallo Cantafio, Vanessa Katia Favasuli, Cecilia Bandini, Giuseppe Viglietto, Roberto Piva, Antonino Neri, Nicola Amodio · 2021 · Cancers
Predicting multi-level drug response with gene expression profile in multiple myeloma using hierarchical ordinal regression
Xinyan Zhang, Bing-Zong Li, Huiying Han, Sha Song, Hongxia Xu, Yating Hong, Nengjun Yi, Wenzhuo Zhuang · 2018 · BMC Cancer
Pan-cancer evaluation of gene expression and somatic alteration data for cancer prognosis prediction
Xingyu Zheng, Christopher Ian Amos, Hildreth Robert Frost · 2021 · BMC Cancer
APOBEC3B reporter myeloma cell lines identify DNA damage response pathways leading to APOBEC3B expression
Hiroyuki Yamazaki, Kotaro Shirakawa, Tadahiko Matsumoto, Yasuhiro Kazuma, Hiroyuki Matsui, Yoshihito Horisawa, Emani Stanford, Anamaria Daniela Sarca, Ryutaro Shirakawa, Keisuke Shindo et al. · 2020 · PLoS ONE
Clinical implications of cytogenetic and molecular aberrations in multiple myeloma
Sarah Goldman‐Mazur, David H. Vesole, Artur J. Jurczyszyn · 2021 · Acta Haematologica Polonica
Identification of key genes and construction of microRNA–mRNA regulatory networks in multiple myeloma by integrated multiple GEO datasets using bioinformatics analysis
Hongyu Gao, Huihan Wang, Wei Yang · 2017 · International Journal of Hematology
Mutational load in carotid body tumor
Anna V. Kudryavtseva, Elena Lukyanova, Dmitry Valerievich Kalinin, Andrew R. Zaretsky, Anatoly V. Pokrovsky, Alexander Leonidovich Golovyuk, Maria Fedorova, Elena A. Pudova, Sergey Kharitonov, Vladislav Pavlov et al. · 2019 · BMC Medical Genomics
Temporal genomic dynamics shape clinical trajectory in multiple myeloma
Maura, Francesco, Kaddoura, Marcella, Poos, Alexandra M., Baughn, Linda B., Ziccheddu, Bachisio, Bärtsch, Marc-Andrea, Cirrincione, Anthony, Maclachlan, Kylee, Chojnacka, Monika, Diamond, Benjamin et al. · 2025 · Nature Genetics
Two States of Myeloma Stem Cells
Shmuel Yaccoby · 2017 · Clinical Lymphoma Myeloma & Leukemia
Mutagenic Activity of AID/APOBEC Deaminases in Antiviral Defense and Carcinogenesis
O. N. Shilova, D. L. Tsyba, E. S. Shilov · 2022 · Molecular Biology
Clinical Outcome-Related Cancer Pathways and Mutational Signatures in Patients With Unresectable Esophageal Squamous Cell Carcinoma Treated With Chemoradiotherapy
Li Li, Jujie Sun, Ning Liu, Ruoying Yu, Junli Zhang, Jiaohui Pang, Qiuxiang Ou, Ying Yin, Jinfeng Cui, Xuling Yao et al. · 2022 · International Journal of Radiation Oncology*Biology*Physics
RNA-sequencing based first choice of treatment and determination of risk in multiple myeloma
Martina Emde, Susanne Beck, Vladimı́r Beneš, Hans Jürgen Salwender, Uta Bertsch, Christof Scheid, Mathias Hänel, Katja Christina Weisel, Thomas Hielscher, Marc Steffen Raab et al. · 2023 · Frontiers in Immunology
Updates on mechanisms of disease progression in precursor myeloma: Monoclonal gammopathy of undermined significance and smoldering myeloma
Cynthia Saade, Irene M. Ghobrial · 2025 · La Presse Médicale
Determinants of Oligonucleotide Selectivity of APOBEC3B
Jeffrey Wagner, Özlem Demir, Michael A. Carpenter, Hideki Aihara, Daniel A. Harki, Reuben S. Harris, Rommie E. Amaro · 2018 · Journal of Chemical Information and Modeling
Multiple Myeloma: Bioinformatic Analysis for Identification of Key Genes and Pathways
Chaimaa Saadoune, Badreddine Nouadi, Hasna Hamdaoui, Fatima Chegdani, Faïza Bennis · 2022 · Bioinformatics and Biology Insights
Human APOBEC3B interacts with the heterogenous nuclear ribonucleoprotein A3 in cancer cells
Nawneet Mishra, K. Sony Reddy, Uddhav Timilsina, Deepak Gaur, Ritu Gaur · 2018 · Journal of Cellular Biochemistry
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1)
Michele Bibas · 2024 · Mediterranean Journal of Hematology and Infectious Diseases
Genomic profiling of multiple myeloma: New insights and modern technologies
Malin L. Hultcrantz, Venkata D. Yellapantula, Even Holth Rustad · 2020 · Best Practice & Research Clinical Haematology
IgH translocation with undefined partners is associated with superior outcome in multiple myeloma patients
Xuehan Mao, Junling Zhuang, Duoduo Zhao, Xiaoqing Li, Xin Du, Mu Hao, Yan Xu, Yuting Yan, Jiahui Liu, Huishou Fan et al. · 2020 · European Journal Of Haematology
High or low? Assessing disease risk in multiple myeloma
Timothy Martin Schmidt · 2022 · Hematology
Morphogens and growth factor signalling in the myeloma bone-lining niche
Emma V. Morris, Claire M. Edwards · 2021 · Cellular and Molecular Life Sciences
Correlation of gene expression and associated mutation profiles of APOBEC3A, APOBEC3B, REV1, UNG, and FHIT with chemosensitivity of cancer cell lines to drug treatment
Suleyman Vural, Richard Simon, Julia Krushkal · 2018 · Human Genomics
Genetic inhibitors of APOBEC3B-induced mutagenesis
Tony M. Mertz, Elizabeth Rice-Reynolds, Ly Thi Huong Nguyen, Anna J. Wood, Cameron Cordero, Nicholas Bray, Victoria Harcy, Rudri K Vyas, Debra Mitchell, Kirill S. Lobachev et al. · 2023 · Genome Research
Smoldering multiple myeloma – Past, present, and future
Hashim Mann, Vatsala Katiyar, Cindy Varga, Raymond L. Comenzo · 2021 · Blood Reviews
Molecular Diagnostic Testing for Hematopoietic Neoplasms
Christopher A. Hergott, Annette S. Kim · 2022 · Clinics in Laboratory Medicine
Structure of the catalytically active APOBEC3G bound to a DNA oligonucleotide inhibitor reveals tetrahedral geometry of the transition state
Atanu Maiti, Adam K. Hedger, Wazo Myint, Vanivilasini Balachandran, Jonathan K. Watts, Celia A. Schiffer, Hiroshi Matsuo · 2022 · Nature Communications
Cytogenetic Abnormalities in Multiple Myeloma: Incidence, Prognostic Significance, and Geographic Heterogeneity in Indian and Western Populations
Pratibha Kadam Amare, Shraddha Nikalje Khasnis, Pranita Hande, Hrushikesh Mukund Lele, Nishigandha Wable, Snehal Kaskar, Nikita Nikam Gujar, Nilesh Gardi, Aniket Prabhudesai, Karishma Todi et al. · 2022 · Cytogenetic and Genome Research
Overexpression of B‐cell lymphoma 6 alters gene expression profile in a myeloma cell line and is associated with decreased DNA damage response
Kenichi Tahara, Makiko Takizawa, Arito Yamane, Yohei Osaki, Takuma Ishizaki, Takeki Mitsui, Akihiko Yokohama, Takayuki Saitoh, Norifumi Tsukamoto, Morio Matsumoto et al. · 2017 · Cancer Science
Genetic Predictors of Mortality in Patients with Multiple Myeloma
Hamza Hassan, Raphael Elie Szalat · 2021 · The Application of Clinical Genetics
Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients
Scott A. Ely, Peter A. Forsberg, Ihsane Ouansafi, Adriana Rossi, Alvin Modin, Roger Niles Pearse, Karen A. Pekle, Arthur Perry, Morton Coleman, David S. Jayabalan et al. · 2017 · Clinical Lymphoma Myeloma & Leukemia
Initial whole-genome sequencing of plasma cell neoplasms in first responders and recovery workers exposed to the World Trade Center attack of September 11, 2001
Maura, Francesco, Diamond, Benjamin, Maclachlan, Kylee H., Derkach, Andriy, Yellapantula, Venkata D., Rustad, Even H., Hultcrantz, Malin, Shah, Urvi A., Hong, Jessica, Landau, Heather J. et al. · 2021 · Clinical Cancer Research
Accuracy of mutational signature software on correlated signatures
Yang Wu, Ellora Hui Zhen Chua, Alvin Wei Tian Ng, Arnoud Boot, Steve Rozen · 2022 · Scientific Reports
Maintaining therapeutic progress in multiple myeloma by integrating genetic and biological advances into the clinic
Gareth John Morgan, Leo Rasche · 2018 · Expert Review of Hematology
The combination of C-Myc rearrangement and 1q21 gain is associated with poor prognosis in multiple myeloma
Yuanyuan Jin, Xiaochen Yu, Jianhua Du, Hui Yan Li, Wenjiao Tang, Congwei Jia, Yunyan Zan, Miao Chen, Yanbin Zhang, Minhong Yu et al. · 2021 · Annals of Hematology
Knowing the unknowns in high risk multiple myeloma
Benjamin Avi Derman, Satyajit Kosuri, Andrzej J. Jakubowiak · 2021 · Blood Reviews
The Challenging Approach to Multiple Myeloma: From Disease Diagnosis and Monitoring to Complications Management
Sonia Morè, Laura Corvatta, Valentina Maria Manieri, Erika Morsia, Massimo Offidani · 2024 · Cancers